DiaMedica Therapeutics (DMAC) Set to Announce Quarterly Earnings on Wednesday

DiaMedica Therapeutics (NASDAQ:DMAC) is set to issue its quarterly earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its earnings results on Wednesday, March 20th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.14).

DiaMedica Therapeutics Price Performance

NASDAQ:DMAC traded up $0.15 during trading hours on Tuesday, reaching $3.65. The company had a trading volume of 91,436 shares, compared to its average volume of 41,877. The firm has a market cap of $138.55 million, a PE ratio of -5.97 and a beta of 1.75. DiaMedica Therapeutics has a 1-year low of $1.58 and a 1-year high of $4.75. The business’s 50 day moving average price is $2.77 and its 200-day moving average price is $2.73.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on DMAC shares. Craig Hallum started coverage on DiaMedica Therapeutics in a report on Wednesday, April 24th. They set a “buy” rating and a $8.00 target price for the company. Oppenheimer reissued an “outperform” rating and issued a $6.00 price objective (down from $7.00) on shares of DiaMedica Therapeutics in a report on Thursday, March 21st.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.